Serwell Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-12-2024
- Paid Up Capital ₹ 0.10 M
as on 17-12-2024
- Company Age 32 Year, 3 Months
- Last Filing with ROC 31 Mar 2017
- Open Charges ₹ 0.75 M
as on 17-12-2024
- Revenue %
(FY 2017)
- Profit -745.00%
(FY 2017)
- Ebitda -545.00%
(FY 2017)
- Net Worth -7.00%
(FY 2017)
- Total Assets -63.53%
(FY 2017)
About Serwell Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2017. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.75 M.
Kizhepate Gopalakrishnan and Madhuraveliath Mohan serve as directors at the Company.
- CIN/LLPIN
U24231KL1992PTC006740
- Company No.
006740
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Oct 1992
- Date of AGM
30 Sep 2017
- Date of Balance Sheet
31 Mar 2017
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Serwell Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madhuraveliath Mohan  | Managing Director | 12-Oct-1992 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kizhepate Gopalakrishnan | Director | 12-Oct-1992 | Current |
Financial Performance of Serwell Pharmaceuticals.
Serwell Pharmaceuticals Pvt Ltd, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 745% decrease in profit. The company's net worth dipped by a decrease of 7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Serwell Pharmaceuticals?
In 2017, Serwell Pharmaceuticals had a promoter holding of 77.00% and a public holding of 23.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Nedungadi Bank Limited Creation Date: 28 Jul 1993 | ₹0.75 M | Open |
How Many Employees Work at Serwell Pharmaceuticals?
Serwell Pharmaceuticals has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Serwell Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Serwell Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
